925 related articles for article (PubMed ID: 23238666)
1. High on treatment platelet reactivity against aspirin by non-steroidal anti-inflammatory drugs--pharmacological mechanisms and clinical relevance.
Hohlfeld T; Saxena A; Schrör K
Thromb Haemost; 2013 May; 109(5):825-33. PubMed ID: 23238666
[TBL] [Abstract][Full Text] [Related]
2. An introduction to aspirin, NSAIDs, and COX-2 inhibitors for the primary prevention of cardiovascular events and cancer and their potential preventive role in bladder carcinogenesis: part I.
Moyad MA
Semin Urol Oncol; 2001 Nov; 19(4):294-305. PubMed ID: 11769881
[TBL] [Abstract][Full Text] [Related]
3. Drug/drug interaction of common NSAIDs with antiplatelet effect of aspirin in human platelets.
Saxena A; Balaramnavar VM; Hohlfeld T; Saxena AK
Eur J Pharmacol; 2013 Dec; 721(1-3):215-24. PubMed ID: 24075938
[TBL] [Abstract][Full Text] [Related]
4. Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin?
Strand V
Lancet; 2007 Dec; 370(9605):2138-51. PubMed ID: 18156036
[TBL] [Abstract][Full Text] [Related]
5. The antiplatelet effect of six non-steroidal anti-inflammatory drugs and their pharmacodynamic interaction with aspirin in healthy volunteers.
Gladding PA; Webster MW; Farrell HB; Zeng IS; Park R; Ruijne N
Am J Cardiol; 2008 Apr; 101(7):1060-3. PubMed ID: 18359332
[TBL] [Abstract][Full Text] [Related]
6. Hemoptysis under diclofenac and antiplatelet doses of aspirin.
Yiannakopoulou EC
Pharmacology; 2011; 87(1-2):1-4. PubMed ID: 21150234
[TBL] [Abstract][Full Text] [Related]
7. An introduction to aspirin, NSAids, and COX-2 inhibitors for the primary prevention of cardiovascular events and cancer and their potential preventive role in bladder carcinogenesis: part II.
Moyad MA
Semin Urol Oncol; 2001 Nov; 19(4):306-16. PubMed ID: 11769882
[TBL] [Abstract][Full Text] [Related]
8. [Recommendations for treatment with nonsteroidal anti-inflammatory drugs].
Bolten WW
MMW Fortschr Med; 2005 Aug; 147(31-32):24-7. PubMed ID: 16128192
[TBL] [Abstract][Full Text] [Related]
9. [Prescription of NSAIDs in patients treatment with platelet inhibitors or anticoagulants].
Avouac B; Combe B; Darné B
Presse Med; 2003 Nov; 32(37 Pt 2):S38-43. PubMed ID: 14763353
[TBL] [Abstract][Full Text] [Related]
10. Variable platelet response to aspirin and clopidogrel in atherothrombotic disease.
Maree AO; Fitzgerald DJ
Circulation; 2007 Apr; 115(16):2196-207. PubMed ID: 17452618
[No Abstract] [Full Text] [Related]
11. [A 100 years of aspirin: a drug with a future?].
Sánchez García P
An R Acad Nac Med (Madr); 1997; 114(1):157-63; discussion 164-7. PubMed ID: 9324911
[No Abstract] [Full Text] [Related]
12. Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis.
Schrör K
Semin Thromb Hemost; 1997; 23(4):349-56. PubMed ID: 9263351
[TBL] [Abstract][Full Text] [Related]
13. Characterization of inhibition of platelet function by paracetamol and its interaction with diclofenac in vitro.
Munsterhjelm E; Niemi TT; Ylikorkala O; Silvanto M; Rosenberg PH
Acta Anaesthesiol Scand; 2005 Jul; 49(6):840-6. PubMed ID: 15954969
[TBL] [Abstract][Full Text] [Related]
14. Cardioprotective effects of aspirin compromised by other NSAIDs.
Gottlieb S
BMJ; 2003 Sep; 327(7414):520. PubMed ID: 12958094
[No Abstract] [Full Text] [Related]
15. Use of nonsteroidal anti-inflammatory drugs in patients with cardiovascular disease: a cautionary tale.
Amer M; Bead VR; Bathon J; Blumenthal RS; Edwards DN
Cardiol Rev; 2010; 18(4):204-12. PubMed ID: 20539104
[TBL] [Abstract][Full Text] [Related]
16. Influence of non-steroidal anti-inflammatory drugs on antiplatelet effect of aspirin.
Yokoyama H; Ito N; Soeda S; Ozaki M; Suzuki Y; Watanabe M; Kashiwakura E; Kawada T; Ikeda N; Tokuoka K; Kitagawa Y; Yamada Y
J Clin Pharm Ther; 2013 Feb; 38(1):12-5. PubMed ID: 22882748
[TBL] [Abstract][Full Text] [Related]
17. Effects of ibuprofen on the magnitude and duration of aspirin's inhibition of platelet aggregation: clinical consequences in stroke prophylaxis.
Gengo FM; Rubin L; Robson M; Rainka M; Gengo MF; Mager DE; Bates V
J Clin Pharmacol; 2008 Jan; 48(1):117-22. PubMed ID: 18094224
[TBL] [Abstract][Full Text] [Related]
18. [Cardiovascular risk of non-steroidal anti-inflammatory drugs].
Hermann M
Praxis (Bern 1994); 2012 Oct; 101(20):1309-14. PubMed ID: 23032496
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.
Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
Am J Manag Care; 2002 Oct; 8(15 Suppl):S392-400. PubMed ID: 12416789
[TBL] [Abstract][Full Text] [Related]
20. Aspirin and cyclooxygenase-2 inhibitors.
Armstrong TA
Am J Health Syst Pharm; 2003 Jul; 60(14):1481. PubMed ID: 12892035
[No Abstract] [Full Text] [Related]
[Next] [New Search]
